Development and implementation of the AIDA international registry for patients with Schnitzler’s syndrome

Jurgen Sota1, Antonio Vitale1, Ewa Więsik-Szewczyk2, Micol Frassi3, Giuseppe Lopalco4, Giacomo Emmi5, Marcello Govoni6, Amato de Paulis7,8, Achille Marino9, Antonio Gidaro10, Sara Monti11, Daniela Opris-Belinski12, Rosa Maria R. Pereira13, Karina Jahnz-Różyk2, Carla Gaggiano1, Francesca Crisafulli3, Florenzo Iannone4, Irene Mattioli5, Francesca Ruffilli6, Ilaria Mormile7, Katarzyna Rybak14, Valeria Caggiano1, Paolo Airò3, Abdurrahman Tufan15, Stefano Gentileschi16, Gaafar Ragab17,18, Ibrahim A. Almaghlouth19,20, Adham Aboul-Fotouh Khalil21, Marco Cattalini22, Francesco La Torre23, Maria Tarsia1, Henrique A. Mayrink Giardini13, Moustafa Ali Saad17, Monica Bocchia24, Federico Caroni24, Teresa Giani25, Elisa Cinotti26, Piero Ruscitti26, Pietro Rubegni25, Marilia A. Dagostin13, Bruno Frediani15, Aslihan Avanoğlu Guler15, Francesca Della Casa7, Maria Cristina Maggio27, Andreas Recke28, Dagmar von Bubnoff28, Karoline Krause29, Alberto Balistreri30, Claudia Fabiani31, Donato Rigante22,32,33, and Luca Cantarini1,†

1Research Center of Systemic Autoinflammatory Diseases and Behçet’s Disease Clinic, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy, 2Department of Internal Medicine, Pulmonology, Allergy and Clinical Immunology, Central Clinical Hospital of the Ministry of National Defence, Military Institute of Medicine, Warsaw, Poland, 3Rheumatology and Clinical Immunology, Spedali Civili and Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, 4Rheumatology Unit, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy, 5Department of Experimental and Clinical Medicine, University of Brescia, Brescia, Italy, 6Rheumatology Unit, Department of Medical Sciences, Azienda Ospedaliero-Universitaria S. Anna - Ferrara, Università di Ferrara, Ferrara, Italy, 7Section of Clinical Immunology, Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy, 8Rheumatology Unit, Division of Biomedical and Clinical Sciences Luigi Sacco, Luigi Sacco Hospital, University of Milan, Milan, Italy, 9Rheumatology Department, Istituto di ricovero e cura a carattere scientifico Policlinico S. Matteo Fondazione, University of Pavia, Pavia, Italy, 10Department of Internal Medicine and Rheumatology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, 11Rheumatology Division, Hospital das Clínicas (HCFMUSP), Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, 12Department of Internal Medicine, Nephrology and Endocrinology, Clinical District Hospital No. 2, Rzeszów, Poland, 13Division of Rheumatology, Department of Internal Medicine, Gazi University Faculty of Medicine, Ankara, Turkey, 14Unit of Rheumatology, Azienda Ospedaliero-Universitaria Senese, Siena, Italy
Introduction

Despite being individually uncommon, rare diseases affect a significant proportion of the general population if taken collectively; they actually represent a huge burden to society in terms of direct and indirect social, economic and healthcare costs (1). In this context a considerable proportion of inpatient burden, hospital admissions, orphan drug sales and impact on community medicine is connected with the management of rare diseases, especially in the Western countries (2–4). Moreover, clinical trials in the field of rare diseases are difficult to conduct due to the low epidemiologic burden. Therefore, based on conventional recruitment methods, clinical trials are sparse and more likely single arm,
non-randomized and open label studies (5). Taken together, these aspects highlight the substantial difficulties that physicians encounter in everyday clinical practice when dealing with rare diseases. In the context of autoinflammatory diseases, these limitations have generated the urgency to develop an international network capable of gathering together the Centers experienced with these conditions worldwide. In this regard, the AutoInflammatory Disease Alliance (AIDA) network has been developed with the aim to represent an international group of physicians and researchers interested in sharing their experience and information on the clinical, therapeutic and research approach to autoinflammatory diseases. This will facilitate a comprehensive description of disease manifestations, their long-term clinical course, prognostic outcomes and a targeted treatment approach tailored according to the patient’s profile in the view of a personalized medicine.

The present paper has been proposed to describe the design, development and deployment of an international disease-specific registry specifically dedicated to Schnitzler’s syndrome in the frame of the AIDA network. Schnitzler’s syndrome is a very rare condition that has many similarities with the hereditary autoinflammatory diseases (6). Pathogenesis along with disease clinical course and prognosis are still far from being fully defined. Therefore, an international registry oriented to this very rare syndrome constitutes a precious source of data to be translated into valuable and solid evidence capable of significantly widening the current evidence on this disorder.

Materials and methods

Study design

The Registry for Schnitzler’s syndrome is classified as a clinical-, physician-driven, population- and electronic-based registry; it was developed along with other autoinflammatory disease-specific registries in the context of AIDA network (7–9).

Participation is open to any Center that deals with Schnitzler’s syndrome regardless of location, medical specialty, or type of practice setting. Centers may join the AIDA network and obtain credentials to access the Registry after having officially requested an involvement into the Network to the study promoter. However, obtaining approval from the local Ethics Committee and appointing a Principal Investigator able to coordinate the study locally and at least one Site Investigator responsible for the documentation and data entry should be considered essential pre-requisites. As data collected refer to information routinely collected in the field of the best standard of care, there is neither cost nor financial compensation for the study participation.

Data collection is made up of a retrospective and a prospective phase: the former refers to the information routinely gathered during the past years of active disease up to the inclusion in the registry; the latter includes clinical, therapeutic, and socioeconomic information collected starting from the moment of enrolment. It is advisable to insert the retrospective data with the patient actively participating in the recruitment, in order to obtain as many details as possible, minimizing missing data and any recall bias. Regarding the prospective collection, data have to be updated at least annually or in case of treatment changes, as for additional therapy and/or posology adjustments.

According to its observational nature, the registry includes demographic, genetic, clinical, laboratory, diagnostic and therapeutic data; long-term outcomes and prognostic variables will also be collected if written informed consent will not be withdrawn over time. Neither the clinical management, nor the adherence to the study is influenced by the study participation in any way.

Study objectives

The primary aim of this registry is to bypass the limitations related to the standard research approach and to remedy the poor number of patients available for each Center.

Other objectives consist in the following points: (I) to fully characterize the disease phenotype and its changes during the long-term follow-up; (II) to point out the prognosis of Schnitzler’s syndrome in the light of the new therapeutic acquisitions; (III) to identify predictive variables to therapeutic response; (IV) to refine the process of differential diagnosis; (V) to analyze the role of posology adjustments when primary or secondary inefficacy occur; (VI) to study the behavior of Schnitzler’s syndrome during pregnancy and post-partum period and possible therapeutic strategies to employ in pregnant or breastfeeding women; (VII) to estimate the socioeconomic impact of Schnitzler’s syndrome and the benefits potentially obtained with therapy; (VIII) to comprehensively define hematological complications in the long-term; (IX) to report the cardiovascular complications in patients with Schnitzler’s syndrome; (X) to develop recommendations useful for everyday clinical management.

As the enrolling process will expand, it would be possible to design more specific and cutting-edge studies according to future unmet needs.

Ethical/legal aspects

The first national regulatory approval of the AIDA Project was obtained in June 2019 by the Ethics Committee of the Azienda Ospedaliero-Universitaria Senese, Siena, Italy (Ref. No. 14951). Later, national, and international expert centers for the diagnosis, clinical management and treatment of autoinflammatory diseases have approved the project before joining the AIDA network.
Patients’ data are kept in accordance with the EU General Data Protection Regulations (GDPR) about the protection and processing of personal data (2016/679/EU) (10).

This project was registered at ClinicalTrials.gov (ID: NCT05200715) and follows the principles of the Declaration of Helsinki.

After having received age-appropriate information sheets, patients (or their parents/legal guardian) have to give their voluntary informed consent; minors aged ≥12 years are also required to provide their assent to be included in the study.

Patients have to properly receive information about aims of the study, terms of data collection and management, rules for data access, and possible withdrawal of the consent to continue data collection. In addition, both patients and Principal Investigators may withdraw their consent for the use of data for statistical analyses at any time. In this case, all gathered data will be deleted soon after the patient and/or Principal Investigator communication to the study promoter.

Patients will not receive any honoraria or other payments for the participation in this project. Also, no relationships to billing of the healthcare system or insurance companies have to be disclosed.

**Patients’ eligibility**

Inclusion criteria for the recruitment into this AIDA Registry consist in the fulfillment of Strasbourg diagnostic criteria for Schnitzler’s syndrome (11). The lack of a written informed consent by the patient or her/his parents or legal guardian accounts for the only exclusion criterium considered in this project.

**Data collection**

Data are collected through the Research Electronic Data Capture (REDCap), a metadata-driven software application and novel metadata-gathering workflow developed at Vanderbilt University Medical Center, routinely used to support translational research projects in the academic research environment (12).

Each Principal and Site Investigator included into the AIDA Project is provided with his/her own password and login identification to access the registry through the REDCap web-interface, insert data on the Instruments of the registry and then review or complete the already inserted information. None of the participating Principal and Site Investigators are allowed to check information uploaded from other Centers.

While the public website (https://aidanetwork.org/en/) may be accessible by anyone who wants to learn more about AIDA network, its objectives and how to participate to the project, the registry website (https://sitbio.med.unisi.it/redcap/redcap_v12.2.7/index.php?pid=28) is hosted on a separate password-protected platform.

Data are stored on a server placed in the University of Siena, Siena, Italy. Ownership of results generated from the analysis of aggregated data will belong to the Promoter.

**Statistical analysis**

Data collected will be converted into an appropriate format for statistical analysis. To this end, a good and reliable statistical plan is warranted according with the specific objectives that will be pursued. The statistical plan will include general principles related to descriptive statistics as well as inferential statistics.

Statistical analysis will take into consideration missing data before performing computations. Given the real-life context of data collection, a threshold level of missing data is set to 25%.

**Results**

**Current numbers and registry development**

Since its launch on November 27th, 2020, the AIDA project has quickly reached a wide geographic coverage: 113 centers have already joined the project around the world (by April 28th, 2022).

To date, 3,924 common data elements (fields) organized into 25 instruments (forms) compose the registry. The full list of instruments and their fields are listed in Table 1. The fields for data collection are organized in such a way as to appear only if patient’s clinical history make necessary to answer, according to a branching structure. Therefore, only a part of the 3,924 fields will initially appear to the investigators, and the number of questions to answer in the registry will depend exclusively on patient’s clinical complexity. Table 2 provides the full list of the objectives of the registry for the future agenda. Figure 1 shows AIDA network distributions around the world.

Data elements correspond to patient’s demographics, medical history, laboratory features, symptoms at onset, symptoms developed over time, comorbidities, cardiovascular risk, work-up exams, pregnancies, long-term clinical outcomes, past and current treatments. On the other hand, longitudinal data are captured through a specific “follow-up” instrument, including disease activity, disease manifestations occurred in the last follow-up period, laboratory exams worn by the patient at the last assessment, any treatment adjustments, clinimetric scores, any hematologic complications, socio-economic details about access to the healthcare system, absenteeism and working capacity.
TABLE 1  List of instruments (to be regarded as “forms”) included in the registry dedicated to patients with Schnitzler’s syndrome, with the corresponding number of common data elements, time-points at which they should refer to and number of mandatory fields.

| Instruments                                      | Fields | Retrospective/prospective phase | No. of mandatory fields |
|--------------------------------------------------|--------|---------------------------------|--------------------------|
| Demographics                                     | 9      | Retrospective phase              | 3                        |
| Consents                                         | 4      | Retrospective/prospective phase  | 1                        |
| Diagnostic data and family history               | 20     | Retrospective phase              | 2                        |
| Features of attacks at the time of disease onset  | 26     | Retrospective phase              | 0                        |
| Features of attacks up to the time of diagnosis   | 44     | Retrospective phase              | 0                        |
| Features of attacks from the diagnosis to the enrolment into the registry | 44 | Retrospective phase | 0 |
| Clinical diagnostic scores and criteria          | 14     | Retrospective/prospective phase  | 0                        |
| Laboratory data                                  | 17     | Retrospective phase              | 1                        |
| Cardiovascular risk                              | 23     | Retrospective phase              | 2                        |
| Past and current treatments                      | 1      | Retrospective phase              | 0                        |
| NSAIDs monotherapy—the retrospective phase       | 74     | Retrospective phase              | 1                        |
| Corticosteroid monotherapy/main therapy—the retrospective phase | 131 | Retrospective phase | 1 |
| Antihistamines—the retrospective phase           | 12     | Retrospective phase              | 0                        |
| Colchicine treatment—the retrospective phase     | 89     | Retrospective phase              | 1                        |
| Treatment with cDMARDs (not associated to biotechnological agents)—the retrospective phase | 387 | Retrospective phase | 6 |
| Treatment with small molecules not associated to biologic agents—the retrospective phase | 756 | Retrospective phase | 12 |
| Treatment with biologic agents—the retrospective phase | 1,022 | Retrospective phase | 14 |
| Fertility and pregnancy                          | 14     | Retrospective/prospective phase  | 1                        |
| Disease course and treatment during pregnancies  | 66     | Retrospective/prospective phase  | 1                        |
| Follow-up visits—the prospective phase           | 647    | Prospective phase                | 55                       |

TABLE 2  Objectives of the registry dedicated to Schnitzler’s syndrome in the platform of AIDA network.

| Objective | Description |
|-----------|-------------|
| Main objective | To bypass the limitations related to the standard research and to remedy the poor number of patients available for studies |
| Other objectives | To fully characterize the disease phenotype and its changes during follow-up |
|             | To point out the prognosis of the syndrome |
|             | To identify predictive variables for the therapeutic response |
|             | To refine the process of differential diagnosis |
|             | To analyze the role of posology adjustments in the case of drug inefficacy |
|             | To study the disease course during pregnancy/post-partum period and eventual therapeutic strategies useful in pregnant or breastfeeding women |
|             | To estimate the socioeconomic impact of the syndrome and the benefits obtained with therapy |
|             | To define long-term hematological complications |
|             | To report the cardiovascular complications |
|             | To develop recommendations useful for routine clinical management |

Patients’ involvement as key stakeholders

In recent years patients have become increasingly aware of their role, which is central in stimulating the research efforts and quality of clinical management. Patient advocacy groups may help by disseminating information, supporting the recruitment of patients, and taking part in regulatory processes. At current, many different associations have already taken part into the AIDA project, as for the Italian Association of Periodic Fevers (A.I.F.P., Associazione Italiana Febbri Periodiche), the National Association for Rheumatologic and Rare Diseases (A.P.M.A.R.R., Associazione Nazionale Persone con Malattie Reumatologiche e Rare), and the National Rheumatic Diseases Association (A.N.M.A.R., Associazione Nazionale Malati Reumatici). The involvement of patients’ associations in other countries is actively ongoing.
to include a higher number of proactive components in the AIDA project.

**Discussion**

Thanks to the new technologies and online tools for the worldwide sharing of information, recent years have witnessed a rapid proliferation of rare diseases registries, which have completely changed the approach to research and participation in international projects. Indeed, according to Orphanet, a European website aimed at providing information about orphan drugs and rare diseases, there are more than 793 current European registries dedicated to rare diseases (13). Their goals are heterogeneous and range from clinical management to epidemiology and research projects; each of them is supported by a wide variety of information systems, data collection and management tools. In this context, the AIDA network has been developed with the aim of overcoming the current issues in the field of rare autoinflammatory diseases, including the fragmentation of knowledge and research affecting Schnitzler's syndrome. This condition is considered as the paradigm of late-onset acquired autoinflammatory syndromes (6). Despite this, the diagnostic delay often accompanied with several misdiagnosis especially during the initial phases, is already remarkable (roughly 5 years), complicating the disease course with significant morbidity due to the lack of a proper treatment. The advent of IL-1 blocking agents on the other hand has dramatically changed the management of Schnitzler's syndrome (14), which are now considered as a first-line therapy. This leads to a considerable health burden with a notable decrease in the quality of life and an even greater impact on the healthcare system. The low incidence and prevalence of Schnitzler's syndrome not only results in a reduced awareness of this condition—and thus the ability to include it in differential diagnosis—but makes it a clinical and therapeutic conundrum. Therefore, an increased awareness is needed among physicians to improve patients’ quality of life and enhance the overall prognosis of this disease, which is still largely dependent on the onset of hematological complications (15).

The development and activation of this international registry represents an invaluable opportunity to widen the knowledge about this unusual disease through the accrual of real-life data, obtaining solid scientific information and final real-world evidence to apply in the everyday medical practice. Its pioneer mission is to create an international network of researchers capable of joining forces for the common purpose to solve the unmet needs that will gradually arise for both patients and physicians.

In this regard, the AIDA network has joined together the different specialties involved in the management of Schnitzler's syndrome, including rheumatologists, dermatologists, immunologists, hematologists, internal medical physicians, and radiologists. These figures may now communicate with each other globally, resulting in the final goal to create an effective strategic approach toward solving this rare disease.

Among other things, this Registry will clarify the geographical distribution of the disease and any change in clinical expression according to the environmental contexts. Also, interesting areas of research would be to fully describe the range of disease manifestations and their change over time; to improve the diagnostic process in the field of systemic inflammatory diseases; to assess the prognosis in the light of the new treatment strategies; to understand which patients are more responsive to a specific therapy; to disclose the proper therapeutic approach when a first biologic line fails; to evaluate how therapy may improve the impact of the disease from a socioeconomic perspective.

The flexibility of the registry allows a rapid implementation of the tool in case of protocol variations. In this regard, the registry has the ability to change with the aim of also meeting future challenges arising from either new scientific acquisition or everyday clinical practice. In addition, the registry has the ability to communicate with any other present or future registry focused on the same disease.

The AIDA Registry for Schnitzler's syndrome shows the typical shortcomings of observational studies. In particular, entering data requires time and attention, especially when the patient's medical history is long or complex in terms of treatment attempts and number of disease complications; in this case, a high frequency of missing data could affect the research potentialities. Furthermore, investigators are not required to consecutively enroll patients followed in their Centers. This could lead to selection biases. Despite these limitations, this registry has the potential to definitively overcome the issues typically associated with the low epidemiological burden and poor number of patients to enroll in clinical trials. The real-life context of data collected in this registry will lead to the achievement of real-life evidence directly applicable in the care of patients with Schnitzler's syndrome. In conclusion,
the development of the AIDA International Registry for patients with Schnitzler’s syndrome will allow the collection of standardized information, enabling international multicentre collaborative research through data sharing and implementation and optimisation of scientific efforts worldwide.

Ethics statement

The studies involving human participants were reviewed and approved by Ethics Committee of the Azienda Ospedaliero-Universitaria Senese, Siena, Italy (Ref. No. 14951). Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

Author contributions

JS wrote the first draft of the manuscript. AV conceived and designed the study and revised the draft of the manuscript. EW-S, MF, GL, GE, MG, AP, AM, AG, SM, DO-B, RP, KJ-R, CG, FCx, FI, IMa, FR, IMo, KR, VC, and PA were involved in data recruitment in the Registry dedicated to patients with Schnitzler’s syndrome. AT, SG, GR, IA, AA-FK, MC, FT, MT, HG, MS, MB, FCa, EC, PRus, PRub, MD, BF, AG, FDC, MM, and CF were included in the authorship as investigators from to the top three contributor centers for any of the other AIDA Registries. AR, DB, and KK were included as leading AIDA experts in the field of Schnitzler’s syndrome. AB is the bioengineer involved in the technical management of the platform and registries. DR took care of the final revision of the manuscript. LC conceived and designed the study and accounted for AIDA Registries Coordinator. Authorship has been established based on the number of data recruited in the AIDA Registries on April 20th, 2022. All authors contributed to the article and approved the submitted version.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Ferreira CR. The burden of rare diseases. Am J Med Genet A. (2019) 179:885–92. doi: 10.1002/ajmg.a.61124
2. Chiu ATG, Chung CCY, Wong WHS, Lee SL, Chung BHY. Healthcare burden of rare diseases in Hong Kong—adopting ORPHACodes in ICD-10 based healthcare administrative datasets. Orphanet J Rare Dis. (2018) 13:147. doi: 10.1186/s13023-018-0892-5
3. Evaluate. (2018). Available online at: http://info.evaluateatagroup.com/eu/607-YGS-364/images/OD2018-IG.pdf (accessed November 5, 2021).
4. Detiček A, Locatelli I, Kos M. Patient access to medicines for rare diseases in European countries. Value Health. (2018) 21:553–60. doi: 10.1016/j.jval.2018.01.007
5. Bell SA, Tudur Smith C. A comparison of interventional clinical trials in rare versus non-rare diseases: an analysis of ClinicalTrials.gov. Orphanet J Rare Dis. (2014) 9:170. doi: 10.1186/s13023-014-0170-0
6. Gudorf I, Lipsker D. Schnitzler syndrome: a review. Curr Rheumatol Rep. (2017) 19:46. doi: 10.1007/s11926-017-0673-5
7. Della Casa F, Vitale A, Pereira RM, Guerriero S, Ragab G, Lopalco G, et al. Development and implementation of the AIDA international registry for patients with non-infectious scleritis. Ophthalmol Ther. (2022) 11:887–97. doi: 10.1007/s40123-022-00466-2
8. Della Casa F, Vitale A, Guerriero S, Sota J, Cimaz R, Ragab G, et al. Development and implementation of the AIDA international registry for patients with non-infectious uveitis. Ophthalmol Ther. (2022) 11:899–911. doi: 10.1007/s40123-022-00459-1
9. Vitale A, Della Casa F, Lopalco G, Ruscitti P, Ciccia F, Emmi G, et al. Development and implementation of the AIDA international registry for patients with Still’s disease. Front Med. (2022) 9:878797. doi: 10.3389/fmed.2022.878797

10. Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the Protection of Natural Persons With Regard to the Processing of Personal Data and on the Free Movement of Such data and Repealing Directive 95/46/EC (General Data Protection Regulation - Text With EEA Relevance). Available online at: https://eur-lex.europa.eu/eli/reg/2016/679/oj (accessed November 15, 2021).
11. Simon A, Adi B, Braun-Falco M, De Koning H, Fermand JP, Grattan C, et al. Schnitzler’s syndrome: diagnosis, treatment, and follow-up. Allergy. (2013) 68:562–8. doi: 10.1111/all.12129
12. Harris PA, Taylor R, Thistle R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. (2009) 42:377–81. doi: 10.1016/j.jbi.2008.08.010
13. Orphanet Report: Rare Diseases Registries in Europe. Available online at: https://www.orpha.net/orphacom/cabioc/docs/G8/Registries.pdf (accessed November 14, 2021).
14. Chu CQ. Schnitzler syndrome and Schnitzler-like syndromes. Chin Med J. (2022). doi: 10.1097/CMJ.0000000000002015. [Epub ahead of print].
15. Dalle S, Balme B, Sebban C, Pariet C, Berger F, Thomas L. Schnitzler syndrome associated with systemic marginal zone B-cell lymphoma. Br J Dermatol. (2006) 155:827–9. doi: 10.1111/j.1365-2133.2006.07417.x

CITATION

Sota J, Vitale A, Wieszak-Szewczyk E, Frassi M, Lopalco G, Emmi G, Govoni M, de Paulis A, Marino A, Gidaro A, Monti S, Oприs-Belinski D, Pereira RMR, Jahnh-Rözyk K, Gaggiiano C, Crisafulli F, Iannone F, Mattioli I, Ruffilli F, Mormile I, Rybak B, Caggiano V, Arö P, Tufan A, Gentilescsi S, Ragab G, Almaglilouth IA, Aboil-Fotouh Khalil A, Cattalini M, La Torre F,
Development and implementation of the AIDA international registry for patients with Schnitzler's syndrome.

Front. Med. 9:931189. doi: 10.3389/fmed.2022.931189

© 2022 Sota, Vitale, Więsiak-Szewczyk, Frassi, Lopalco, Emmi, Govoni, de Paulis, Marino, Gidaro, Monti, Opris-Belinski, Pereira, Jahnz-Rózyk, Gaggiano, Crisafulli, Iannone, Mattioli, Ruffilli, Mormile, Rybak, Caggiano, Airò, Tufan, Gentileschi, Ragab, Almaghlouth, Aboul-Fotouh Khalil, Cattalini, La Torre, Tarsia, Giardini, Ali Saad, Bocchia, Caroni, Giani, Cinotti, Ruscitti, Rubegni, Dagostin, Frediani, Guler, Della Casa, Maggio, Recke, von Bubnoff, Krause, Balistreri, Fabiani, Rigante and Cantarini. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.